Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Group Medical Polymer CoSHWGF 57 Return-on-Tangible-Asset is 3.90% as of Dec. 2025, which is 57% below its 10-year median of 9.00. GuruFocus rates SHWGF with a GF Score™ of 57/100 and a GF Value™ of $0.79 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 66.59% on this metric.
SHWGF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.29 Med: 9 Max: 11.39
Current: 5.29
During the past 13 years, Shandong Weigao Group Medical Polymer Co's highest Return-on-Tangible-Asset was 11.39%. The lowest was 5.29%. And the median was 9.00%.
SHWGF's Return-on-Tangible-Asset is ranked better than 66.59% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs SHWGF: 5.29
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Asset Related Terms
Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Asset Chart
Shandong Weigao Group Medical Polymer Co Annual Data
SHWGF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 3.90% mean?
Shandong Weigao Group Medical Polymer Co (SHWGF) has a Return-on-Tangible-Asset of 3.90% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is 57% below median its historical median of 9.00. Over the past decade, Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset has ranged from 5.29 to 11.39. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #286 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 33.4%.
Is Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset too high?
Shandong Weigao Group Medical Polymer Co's current Return-on-Tangible-Asset of 3.90% is 57% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 5.29 to a high of 11.39. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Shandong Weigao Group Medical Polymer Co's value of 3.90% is 555.5% above this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #286 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #286 out of 856 companies for Return-on-Tangible-Asset. This puts Shandong Weigao Group Medical Polymer Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Shandong Weigao Group Medical Polymer Co's value of 3.90% is 555.5% above this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own Return-on-Tangible-Asset has ranged from 5.29 to 11.39 over the past decade. While the company's 10-year median is 9.00 vs. the industry median of 0.60, Shandong Weigao Group Medical Polymer Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current Return-on-Tangible-Asset of 3.90% is 555.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current Return-on-Tangible-Asset is 3.90%, which is 57% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.79, compared to a current price of $0.43 — trading 45% below its estimated fair value. The current Return-on-Tangible-Asset is 3.90%, which is 57% below median its 10-year median of 9.00 and 555.5% above the Medical Devices & Instruments industry median of 0.60. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGF), the current Return-on-Tangible-Asset is 3.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGF) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $0.43 is trading 45% below its estimated GF Value™ of $0.79.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGF:
Return-on-Tangible-Asset: 3.90% (57% below median its 10-year median of 9.00)
GF Value™: $0.79 vs. price of $0.43 (45% below fair value)
Industry Position: 555.5% above the Medical Devices & Instruments median (#286 of 856)
No single metric tells the full story. See the SHWGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
57GF Score
Get the complete analysis for SHWGF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGF has been successfully added to your 
